Lupus News and Research

Latest Lupus News and Research

Feinstein Institute to train clinicians on how to better care for patients with schizophrenia

The Zucker Hillside Hospital campus of the Feinstein Institute for Medical Research has been approved for a $9.3+ million federal grant to train clinicians on how to better care for patients with schizophrenia.

26 Jun 2012

Rensselaer Center for Stem Cell Research launches today

Ground-breaking research to advance the application of stem cells to address critical injuries and diseases will be taking place at Rensselaer Polytechnic Institute, in a new center funded by New York state and opened today.

From Thermo Fisher Scientific Inc. 23 Jun 2012

Report: Autoimmune diseases are all being diagnosed at rapid rates

There is a disturbing trend in autoimmune disease diagnosis; many are on the upswing. Recent reports show that type 1 diabetes (an autoimmune disease not related to obesity), celiac disease and lupus, among others autoimmune diseases, are all being diagnosed at rapid rates.

22 Jun 2012

Hypertension-associated hospitalizations of children on the increase

The number of children hospitalized with hypertension in the USA increased dramatically between 1997 and 2006, with associated increases in healthcare costs, say researchers.

20 Jun 2012

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.

19 Jun 2012

LFA announces 2012 Gina M. Finzi Memorial Student Fellowship Program grantees

The Lupus Foundation of America (LFA) is pleased to announce the 2012 Gina M. Finzi Memorial Student Fellowship Program grantees. This unique program, established more than 25 years ago by former LFA President Dr. Sergio Finzi in honor of his daughter Gina who passed away from lupus, seeks to cultivate an interest in lupus research among young scientists by funding basic, clinical, translational, epidemiological, and behavioral research studies under the supervision of an established investigator.

15 Jun 2012

Psoriasis link with autoimmune diseases underscored

Patients with psoriasis are nearly twice as likely to have an autoimmune disease as individuals without the condition, suggest study findings.

8 Jun 2012

IRCM researchers make important breakthrough in the field of immunology

A team of researchers at the IRCM led by Dr. Andr- Veillette made an important breakthrough in the field of immunology, which will be published online today by the scientific journal Immunity. The scientists explained a poorly understood molecular mechanism associated with a human immune disorder known as XLP disease or Duncan's syndrome.

8 Jun 2012

Omentum appears to play an important role in regulating the immune system

A fatty membrane in the belly called the omentum has until recently been considered somewhat like the appendix -- it didn't seem to serve much purpose. But Loyola University Chicago Stritch School of Medicine researchers have found that the omentum appears to play an important role in regulating the immune system.

7 Jun 2012

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

6 Jun 2012

Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012

Active Biotech and Ipsen today presented overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific conference "2012 ASCO Annual Meeting" held in Chicago (USA).

5 Jun 2012

Variation in microRNAs may explain survival differences in breast cancer

Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered a potential explanation for why breast cancer is not experienced the same way with African American and Caucasian patients.

4 Jun 2012

New Lupus Insight Prize to be awarded to outstanding investigator

Lupus organizations have come together to launch a first-of-a-kind initiative to encourage scientific advances in lupus research.

1 Jun 2012

Pharmspective releases ‘Molecular Diagnostics Insights in Oncology’

Pharmspective, LLC today announced the release of its second syndicated report – Molecular Diagnostics Insights in Oncology. This new extensive survey of over 400 oncologists characterizes the emerging molecular diagnostics landscape and the role and influence of specific assays in clinical management and therapy selection.

31 May 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

LabCorp, XDx partner to develop and commercialize SLE flare predictor test

XDx, Inc. announced today that it has entered into a collaboration and license agreement with Laboratory Corporation of America Holdings (LabCorp)whereby each party will collaborate in marker discovery, and LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus.

24 May 2012

Severe hypersensitivity reactions to anti-HIV drug occur through autoimmune mechanism

Potentially severe hypersensitivity reactions to the anti-HIV drug abacavir occur through an autoimmune mechanism, resulting from the creation of drug-induced immunogens that are attacked by the body's immune system, according to a study published online by the journal AIDS, official journal of the International AIDS Society.

23 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

Ipsen, Active Biotech complete half of planned recruitment in tasquinimod phase III study for CRPC

Active Biotech and Ipsen today announced that recruitment to the global, pivotal, randomized, double-blind, placebo-controlled phase III study of tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC) has reached an inclusion of 600 patients, half of the planned accrual.

21 May 2012

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012.

18 May 2012